Pfizer announced that the BRAFTOVI® (encorafenib) regimen—combining encorafenib with cetuximab (ERBITUX®) and the chemotherapy backbone FOLFIRI—produced a statistically significant improvement in progression‑free survival in patients with metastatic colorectal cancer carrying a BRAF V600E mutation.
The data come from Cohort 3 of the pivotal BREAKWATER trial, a randomized study that compared the BRAFTOVI regimen to standard chemotherapy with or without bevacizumab. In this cohort, the combination therapy achieved an overall response rate of 60.9% versus 40.0% for the comparator arm, and the PFS benefit met the prespecified statistical threshold.
These results support the investigational BRAFTOVI + FOLFIRI regimen and reinforce Pfizer’s precision‑medicine strategy, especially after the Seagen acquisition. The same drug combination with mFOLFOX6 already received accelerated FDA approval in December 2024, and the new data will help Pfizer seek expanded approval or confirmatory evidence for the FOLFIRI backbone.
Jeff Legos, Pfizer’s Chief Oncology Officer, said the data demonstrate a meaningful benefit and underscore BRAFTOVI’s potential as a practice‑changing treatment for patients with this high‑risk mutation.
The positive PFS outcome positions Pfizer to strengthen its oncology portfolio in a niche market where treatment options have been limited, potentially increasing future revenue from a high‑margin targeted therapy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.